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Background: When antiretroviral therapy does not fully suppress HIV replication, suboptimal levels of
antiretrovirals can select for antiretroviral resistant variants of HIV. These variants may exhibit reduced
replication capacity and result in lower viral loads in blood. Our study evaluated whether antiretroviral
resistance was associated with viral loads in the cerebrospinal ﬂuid (CSF) and better neuropsychological
(NP) performance.
Methods: We enrolled 94 participants and each participant underwent a comprehensive neuromedical
evaluation that used structured clinical assessments of medical history, ART and other medication use,
comprehensive NP testing, and neurological and general physical signs of disease. Blood was collected by
venipuncture, and all participants were offered lumbar puncture. Univariate and multivariate statistical
methods were used to analyze the relationship between antiretroviral resistance, blood and CSF HIV RNA
levels, substance use, and NP performance.
Results: Antiretroviral resistance, detected in blood, was associated with lower CSF viral loads (pb0.01) and
better NP performance (p=0.04) in multivariate analyses, independent of past and current ARV use and
blood viral loads (model: pb0.01). However, HIV RNA levels in CSF did not independently correlate with NP
performance. Low viral loads in the CSF limited our ability to investigate the relationship between
antiretroviral resistance detected in CSF and NP performance.
Conclusions: Even in the absence of ART, antiretroviral resistance-associated mutations correlate with better
NP performance possibly because these mutations reﬂect reduced neurovirulence compared with wild-type
HIV.Published by Elsevier Inc.Background
HIV-associated neurocognitive disorders (HAND) range in severity
from disabling dementia to asymptomatic cognitive, motor, and
behavioral changes.With the widespread use of antiretroviral therapy
(ART) in economically privileged countries, the incidence of HIV-
associated dementia (HAD), characterized by severe neuropsycho-
logical (NP) impairment and inability to perform activities of dailyonal Institutes of Health grants
AI27670, AI38858, AI43638,
search Viral Pathogenesis Core
the San Diego Veterans Affairs
La Jolla, CA 92093-0679, USA.
r).
Inc.living, has signiﬁcantly decreased (reviewed in Deutsch et al., 2001;
Sacktor, 2002). Despite a decrease in incident HAD, less severe forms
of HAND have persisted (Antinori et al., 2002; Giancola et al., 2006;
Antinori et al., 2007; Tozzi et al., 2007) andmay actually be increasing
as HIV-infected individuals live longer (reviewed in McArthur, 2004;
Ances and Ellis, 2007). Comorbidities that are common in individuals
infected with HIV, like hepatitis C virus (HCV) infection and
methamphetamine abuse, are also associated with NP impairment
and may make it difﬁcult to distinguish the contribution of each to NP
impairment (Rippeth et al., 2004; Clifford et al., 2005; Letendre et al.,
2005, 2007; Cherner et al., 2005; Richardson et al., 2005).
Effective ART, as assessed by suppression of blood plasma viral
load, is considered the standard of care for HAND; however, poor
penetration into the central nervous system (CNS) by some
antiretroviral drugs suggests that suppression of blood plasma viral
load may not be an adequate guide when selecting treatment options
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concentrations could select for resistance-associated mutations
(Letendre et al., 2004; Antinori et al., 2005). Studies that have
examined cerebrospinal ﬂuid (CSF) viral loads in the setting of ART
and antiretroviral resistance suggest that ART lowers CSF viral loads
even in the setting of antiretroviral resistance; however, the clinical
signiﬁcance of these ﬁndings remains unclear (Antinori et al., 2005;
Spudich et al., 2006).
In addition, resistance-associated mutations can affect HIV
replication and ﬁtness in the presence or absence of ART. Studies
have examined the relationship between resistance-associated
mutations, in vivo viral load, and HIV disease (Samri et al., 2000;
Schmitt et al., 2000; Antinori et al., 2001; Deeks et al., 2001; Barbour et
al., 2002; Campbell et al., 2003; Paredes et al., 2009). These studies,
however, were limited to blood viral loads and focused on indicators
of HIV disease in the blood, like CD4+ cell counts. Considerably less is
known about the impact of antiretroviral resistance on CSF viral load
and the brain. To this end, we investigated the relationships between
resistance-associated mutations, viral loads in blood and CSF, and NP
performance.
Methods
Eligibility
Our study consisted of 94 participants enrolled in a research study
at the University of California San Diego's HIV Neurobehavioral
Research Center. Participant bloodwas collected by venipuncture, and
for sequencing purposes only, participants with at least 500 HIV RNA
copies/ml in blood plasma were included in this study. All
participants were offered lumbar puncture with 69 consenting and
having a successful procedure. Participants were excluded if they had
signiﬁcant head trauma, brain surgery, cerebral palsy, seizure
disorder, or history of CNS opportunistic infection or received
treatment with interferon-alpha. All subjects provided informed
consent according to a protocol approved by the UCSD Human
Research Protections Program.
Study design and statistical analyses
To investigate the relationship between antiretroviral resistance
detected in blood and HIV RNA levels in blood and CSF, we utilized
univariate andmultivariate analyses. First, we examined demographic
and medical characteristics of study participants in association with
the presence or absence of resistance-associated mutations. HIV RNA
levels in blood and CSF were log transformed to stabilize variances.
Fisher's exact tests were used to compare categorical or binary
measures and Wilcoxon rank sum tests were used to compare
continuous measures. Multiple regressions were performed using CSF
HIV RNA or blood HIV RNA as the continuous outcome and the
detection of antiretroviral resistance in blood as the main predictor of
interest. Other variables used in this model included past and current
ART use, methamphetamine dependence, estimated duration of
infection, and plasma HIV RNA levels. Analyses of CSF HIV RNA levels
were limited to the 69 participants with successfully completed
lumbar punctures. These analyses included the use of Tobit analyses
to adjust for censored data because HIV RNA levels are subject to limit
of detection censoring (Tobin, 1958). In addition, the demographic
and medical characteristics of study participants for whom CSF HIV
RNA were available were compared with the other study participants
to assess the informativeness of the missing data.
To examine the impact of antiretroviral resistance on the
relationship between CSF HIV RNA levels and NP performance, we
utilized both univariate and multivariate approaches. The univariate
approach consisted of a series of univariate analyses with participants
grouped by the presence or absence of antiretroviral resistance. Theﬁrst examined the relationship between CSF HIV RNA levels and NP
performance and the second examined the relationship between
blood HIV RNA levels and NP performance. Because ongoing ART use
can signiﬁcantly alter CSF and blood HIV RNA levels (Spudich et al.,
2006; Marra et al., 2009), we excluded participants currently receiv-
ing ART. This univariate analysis was limited by the number of
participants (i.e., power) and it does not control for other potentially
confounding variables. To more effectively address these concerns,
we performed additional multivariate analyses that included all
available data and incorporated models that allowed us to address
current and past ART and a number of other important factors that
may inﬂuence the relationship between CSF viral load and NP
performance including methamphetamine dependence, current and
nadir CD4 count, and estimated duration of infection. Using this
multivariate approach, we were able to examine if resistance had an
impact on NP performance independent of current and past ART use
and if resistance had an impact on NP performance independent of
CSF HIV RNA levels.
In exploratory analysis, we examined genotypic discordance
between blood and CSF among those with blood and CSF resistance
data available. Resistance discordance was deﬁned as the presence of
one or more resistance-associatedmutation(s) in blood not present in
the CSF or vice versa. We limited the analysis of resistance
discordance to amino acids with a Stanford HIV Resistance Database
“mutation score” of 30 or greater (http://hivdb.stanford.edu,
March 2009). In further exploratory analyses of viral genetic
discordance, Fisher's exact tests were used to compare categorical
or binary measures and the Wilcoxon rank sum tests to examine if
resistance discordance altered HIV RNA levels. As univariate analyses
were not informative, multivariate analysis was not performed.
Statistical analyses were performed using JMP (version 5.0 for Mac;
SAS Institute, Cary, NC) and R version 2.3.1 (R Development Core
Team 2006).
Neuromedical and neuropsychological testing
Participants underwent standardized NP assessments of seven
ability domains (learning, delayed recall, verbal ﬂuency, processing
speed, attention/working memory, abstraction/executive functioning,
motor speed), as previously described (Heaton et al., 2008; Rippeth
et al., 2004). All NP tests were administered and scored by trained
psychometrists using demographically corrected normative data.
Results were summarized by a neuropsychologist using global ratings
that range from 1 (above average) to 9 (severely impaired), based on
the demographically adjusted test scores in the seven ability domains.
A global score of 5 or higher denotesNP impairment that is present in at
least two ability areas (Woods et al., 2004).
At the time of their NP testing and clinical sample collection, the
urine of each participant was screened with a point-of-care test for
common recreational drugs, including amphetamines, cocaine, barbi-
turates, tetrahydrocannabinol, opiates, benzodiazepines, and phency-
clidines (Rapid Response; Biotechnostix, Inc., Markham, Ontario,
Canada). In addition, participants received a Breathalyzer test to
evaluate alcohol intoxication (Alcohol Countermeasure Systems,
Toronto, Ontario, Canada). NP testing was rescheduled if alcohol
was detected or if the participant's urine was positive for non-
prescribed substances, with the exception of cannabis, given its long
elimination period. Likewise, participants were not tested if they
appeared to be intoxicated or in withdrawal.
Methamphetamine dependence was determined with the Struc-
tured Clinical Interview from the Diagnostic and Statistical Manual of
Mental Disorders version IV (Spitzer, 1995). Inclusion in the parent
study from which the methamphetamine users were drawn required
lifetime dependence and evidence of use within the previous
18 months as well as a minimum of 10 days of abstinence prior to
NP testing.
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Blood was collected by venipuncture and CSF was collected by
lumbar puncture. HIV and HCV infections were diagnosed by serology.
HIV RNA levels in blood plasma and CSF were measured (Amplicor
HIV-1Monitor; Roche Diagnostics, Branchburg, NJ). The ultrasensitive
assay was used for CSF (lower limit level of detection of 50 copies/ml)
and the standard assay was used for blood (lower limit level of
detection of 400 copies/ml). A ﬂuorescence-activated cell sorter
quantiﬁed CD4 lymphocytes. The ViroSeq HIV genotyping system
(Applied Biosystems, Alameda, CA) was used for population-based pol
sequencing of HIV RNA extracted from blood plasma per manu-
facturer instructions (Smith et al., 2007). Genotyping of the reverse
transcriptase coding region of CSF-derived HIV RNA included cDNA
synthesis with RETROscript kit (Applied Biosystems) using random
decamers according to the manufacture's protocol. Followed by two
rounds of ampliﬁcation with Taq polymerase (Invitrogen, Carlsbad,
California) as previously described (Koelsch et al., 2003), using
primers CI-Pol 1 and 3RT at cycling parameters: 95 °C×2 min;
95 °C×30 s, 50 °C×I min, 72 °C×1 min for 35 cycles; 72 °C×10 min
and primers 5RT and 3RT at cycling parameters: 95 °C×2 min;
95 °C×30 s, 50 °C×I min, 72 °C×1 min for 35 cycles; 72 °C×10 min.
All assays included negative controls with PCR products visualized by
agarose gel electrophoresis and were conducted in conditions to
minimize PCR contamination. Sequencing was performed on an ABI
3100 Genetic and sequences were manually reviewed using BioEdit
and ViroSeq genotyping software (version 2.4.2; Applied Biosystems).
The Stanford HIV Resistance Database (http://hivdb.stanford.edu,
March 2009) was used to interpret antiretroviral resistance from
genotypic data.
Results
Study participants and antiretroviral resistance
Participants were mostly Caucasian men in their mid-30s
(median=35 years). The median HIV RNA levels were 4.7 (blood)
and 2.9 (CSF) log10 copies/ml. Themedian blood CD4+ cell count was
319/μl, and 25% of participants had a positive serology for HCV. As
expected, methamphetamine use was common in the cohort with 57%
of participants reporting a history of abuse or dependence (Table 1).
Lumbar punctures were successfully performed on 73% of participants
(69 of 94). Clinical and demographic characteristics of participants
with successful lumbar punctures resembled participants withoutTable 1
Participant demographics and clinical characteristics.
Overall
Sample size 94
Age (years) 35
Sex (male) 92%
Ethnicity (non-Caucasian) 37%
Education (years) 12
Duration of HIV (years) 5.3
HIV RNA, CSF (log10 copies/ml)a 2.9
HIV RNA, plasma (log10 copies/ml) 4.7
CD4 count, current (/μL) 319
CD4 count, nadir (/μL) 216
AIDS diagnosis 47%
Past ARV use 63%
Current ARV use 29%
−Adherence (b95% in 4 weeks) 53%
HCV seropositive 25%
Methamphetamine abuse ever 57%
Values are medians or proportions; n=94.
The p-values are based on univariate analyses. Individuals with drug resistance (AR+) differ
plasma HIV RNA, past antiretroviral (ARV) use, and current ARV use.
a Subgroup analysis.lumbar punctures (data not shown), except that participants who did
not undergo lumbar puncture had longer estimated durations of HIV
infection (mean=8.5 vs. 5.5 years, p=0.02).
At the time of study evaluation, 63% had a past history of ART use
and 29% were receiving ART at the time of participation and sampling.
One or more resistance-associated mutations were detected in the
blood plasma of 48 of the 94 study participants (51%). The most
common mutations, M184V and K103N, were detected in 22% and
16% of participants, respectively (Supplementary Table 1). Univariate
analyses demonstrated that individuals with antiretroviral resistance
(AR+) differed from those with no antiretroviral resistance (AR−) in
duration of HIV infection, levels of CSF and blood plasma HIV RNA,
past ART use, and current ART use (Table 1). Participants with
resistant virus did not differ in current CD4+ cell count, CD4+ cell
nadir, HCV serostatus, or diagnosis of AIDS (Table 1).
Resistance proﬁles for the reverse transcriptase coding region
derived from HIV RNA from CSF were obtained for 26 participants.
Median CSF viral loads for these participants were higher than for
those participants for whom resistance proﬁles could not be obtained
(3.16 vs. 2.6 log10 copies/ml, p=.013) but did not differ with regard
to demographic characteristics, current CD4+ cell count, CD4+ cell
nadir, HCV serostatus, or diagnosis of AIDS (data not shown).
Resistance-associated mutations in the reverse transcriptase coding
region fromHIV RNA populations in the CSF were identiﬁed in 4 (15%)
of these 26 participants. Genotypic discordance between blood and
CSF, deﬁned as the presence of one or more resistance-associated
mutation in blood not present in CSF or vice versa, was found in one of
these 4 participants (25%) (Supplementary Table 2). In all but one
case, participants with a major resistance-associated mutation(s) in
blood also had the mutation(s) in the CSF.
Antiretroviral resistance and CSF viral loads
In univariate analyses, lower CSF viral loads were associated with
the presence of antiretroviral resistance in blood-derived virus, lower
HIV blood viral load, and current ARVuse.Multivariate analyses,which
included adjustments for current and past ART use and blood viral
load, demonstrated that lower CSF HIV RNA levels were associated
with the presence of antiretroviral resistance in blood (model:
pb0.01). This relationship was particularly strong for participants
with the M184V mutation (model: pb0.01). Among the 26 partici-
pants with completed CSF resistance proﬁles of reverse transcriptase,
univariate analysis did not indicate differences in CSF viral loads
between individuals with and without evidence of resistance in CSF.AR+ (range) AR− (range) p-value
48 46
34 (23–39) 35 (21–51) N0.10
96% 88% N0.10
38% 37% N0.10
12 (9–20) 12 (6–18) N0.10
8.1 (.052–16.4) 4.1 (0–16.9) b0.01
2.6 (1.7–4.4) 3.3 (1.7–6.2) b0.01
4.4 (2.8–6) 4.8 (3.3–6.3) b0.05
340 (4–1188) 308 (3–1296) N0.10
200 (0–772) 269 (0–1296) N0.10
50% 43% N0.10
73% 51% b0.05
50% 7% b0.001
50% 75% N0.10
25% 24% N0.10
51% 63% N0.10
ed from those with no drug resistance (AR−) in duration of HIV infection, CSF HIV RNA,
Fig. 1. Univariate analysis of CSF HIV RNA levels and neuropsychological performance.
Conﬁdence ellipses (global rating vs. CSF viral load) for individuals without
antiretroviral resistance (AR−) (rho=0.27, p=0.14) and individuals with antiretro-
viral resistance (AR+) (rho=−0.07, p=0.78) demonstrate that the correlation
between global rating and CSF viral load is stronger in individuals without
antiretroviral resistance than in individuals with antiretroviral resistance, although
this did not reach statistical signiﬁcance. To exclude any direct ART effect, this analysis
excluded participants on ART at the time of the study.
Table 2
Summary of multivariate regressions modeling neuropsychological performance.
Coefﬁcient p-value
Model A. NP performance as a function of antiretroviral resistance,
methamphetamine abuse, HIV infection duration, and ARV use
Intercept 3.96 b0.0001
Antiretroviral resistance (blood) −0.88 0.02
Duration of HIV (years) 0.07 0.06
Methamphetamine abuse ever 0.76 0.03
ARV use 0.38 0.40
Adjusted R2=0.12
Model B. NP performance as a function of antiretroviral resistance, methamphetamine
abuse, HIV infection duration, and ARV use and CSF HIV RNA levels
Intercept 3.31 b0.0001
Antiretroviral resistance (blood) −0.79 0.05
Duration of HIV (years) 0.07 0.06
Methamphetamine abuse ever 0.83 0.02
ARV use 0.47 0.31
HIV RNA, CSF (log10 copies/ml) 0.18 0.35
Adjusted R2=0.12
Model C. NP performance as a function of antiretroviral resistance, methamphetamine
abuse, HIV infection duration, and ARV use and plasma HIV RNA levels
Intercept 3.33 b0.0001
Antiretroviral resistance (blood) −0.67 0.04
Duration of HIV (years) 0.04 0.23
Methamphetamine abuse ever 0.76 0.01
ARV use 0.56 0.16
HIV RNA, plasma (log10 copies/ml) 0.150 0.45
Adjusted R2=.09
In multivariate analysis, antiretroviral resistance was found to be associated with NP
performance, although no signiﬁcant relationship between CSF HIV RNA and NP
performance was observed. Antiretroviral use, blood viral load, and CSF viral load did
not explain additional variance in NP performance.
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and neuropsychological performance
To examine the impact of antiretroviral resistance on the
relationship between CSF viral load and NP performance, we
conducted univariate analyses with participants stratiﬁed by the
presence or absence of antiretroviral resistance. The ﬁrst examined
the relationship between CSF viral load and NP performance, and the
second examined the relationship between blood viral load and NP
performance. Because ART use can signiﬁcantly alter CSF and blood
viral load, we excluded participants currently receiving ART. In these
analyses, the correlation between global rating and CSF viral load was
stronger in individuals without antiretroviral resistance than in
individuals with antiretroviral resistance, although this differenceFig. 2. Univariate analysis of blood HIV RNA levels and neuropsychological
performance. Conﬁdence ellipses (global rating vs. plasma viral load) for individuals
without antiretroviral resistance (AR−) (rho=0.25, p=0.10) and individuals with
antiretroviral resistance (AR+) (rho=−0.16, p=0.29) demonstrate that although
not statistically signiﬁcant, the correlation between global rating and plasma viral load
is stronger in individuals without antiretroviral resistance than in individuals with
antiretroviral resistance. To exclude any direct ART effect, this analysis excluded
participants on ART at the time of the study.did not reach statistical signiﬁcance (Fig. 1). The correlation between
global rating and blood viral load was also stronger in individuals
without antiretroviral resistance (AR−) than in individuals with
antiretroviral resistance (Fig. 2). Multivariate analysis demonstrated
that antiretroviral resistance in blood-derived virus (β=−0.88 ;
p=0.024) was associated with better NP performance (model:
adjusted R2=0.12, p=0.017) (Table 2 ). The opposite was observed
for methamphetamine dependence (β=0.76; p=0.031) and dura-
tion of HIV infection (β=0.073 ; p=0.057): each was independently
associated with worse NP performance (Table 2). Similar results were
observed when log-transformed CSF viral load was added to the
analysis as a predictor. In multivariate analyses, antiretroviral use,
blood viral load, and CSF viral load did not explain additional variance
in NP performance. Antiretroviral resistance was found to be
associated with both CSF HIV RNA levels and NP performance,
although no signiﬁcant relationship between CSF HIV RNA and NP
performance was observed.
Discussion
We found that the detection of antiretroviral resistance in HIV
populations in blood was signiﬁcantly associated with both lower CSF
HIV RNA levels and better NP performance. These ﬁndingsmay help to
explain what appears to be a weakening relationship between CSF
viral load and NP performance in the modern treatment era (Brew
et al., 1997; Ellis et al., 1997; McArthur et al., 1997). Thus, in our study
and in other more recent reports (Sevigny et al., 2004; Vitiello et al.,
2007), CSF HIV RNA levels were not independently associated with
betterNPperformance. Taken together, these studies provide evidence
that HIV variants harboring resistance-associated mutations may be
less replication competent and less neurovirulent than wild-type HIV.
Single mutations within pol can result in reduced replication
capacity in vitro (Goudsmitt et al., 1996, Harrigan et al., 1998; White
et al., 2002; Collins et al., 2004; Cong et al., 2007). Single amino acid
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replication capacity include nucleoside reverse transcriptase inhib-
itor (NRTI)-associated mutations (K65R, T215Y, and M184V) and
non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated
mutations (V106A, Y188H, and G190S) (Iglesias-Ussel et al., 2002;
Collins et al., 2004; Weber et al., 2005; Wang et al., 2006; Martinez-
Picado and Martinez, 2008). Our study extends these observations
by demonstrating that resistance-associated mutations known to
reduce replication capacity in vitro, particularly M184V, are asso-
ciated with lower CSF viral loads, independent of past and current
ART use. In contrast, the NNRTI-associated mutation K103N was not
associated with lower viral loads, as might be predicted from its
negligible reduction in replication capacity in vitro (Nicastri et al.,
2004; Koval et al., 2006).
Suboptimal ART may select for HIV that is less replication
competent and less neuropathogenic, but ongoing HIV replication
regardless of phenotype leads to brain injury in a substantial
proportion of untreated individuals. Although this investigation
suggests that resistance-associated mutations may beneﬁt the
nervous system, this beneﬁt is unlikely to match that from virologic
suppression. In addition, compensatory mutations may accumulate
that restore replication capacity while maintaining antiretroviral
resistance. Understanding how individual resistance-associated
mutations contribute to HAND is difﬁcult, given no standard in vitro
method to characterize HIV phenotypes by neurovirulence exists. One
approach that might yield additional insight is to use an in vitro assay
that utilizes microglia or brain macrophages, the likely cell types
productively infected by HIV in the brain (reviewed in Fischer-Smith
et al., 2008), to assess the replication capacity of speciﬁc resistance-
associated mutations (Perez-Bercoff et al., 2007).
Some limitations of this study should be acknowledged. It
analyzed retrospectively an existing cohort with specimens only
from participants with detectable blood viral loads. In addition,
analyses of CSF viral load were based on a subset of participants
with available lumbar punctures. While detailed analysis demon-
strated that this subset did not signiﬁcantly differ from the other
participants in the study, selection bias is possible. Analyses of
antiretroviral resistance also were primarily based on HIV RNA
extracted from blood. We did investigate CSF resistance proﬁles for
26 participants, but genotypic assessment was limited because viral
loads were low in the CSF, which limited sequencing of the reverse
transcriptase coding region. In all but one case, participants with a
major resistance-associated mutation(s) in blood also had the
mutation(s) in the CSF. This degree of concordance in CSF and
blood resistance-associated mutations is likely explained in part by
regimen stability, as the median time on current ART regimen for
these participants was 10 months. Although current ART therapy
was relatively stable, different ART regimens among participants
and a wide range in time on and off ART made it difﬁcult to employ
a more rigorous assessment of ART use. Even though our analysis
was nested in a well-characterized cohort and is one of largest
studies of its kind, these limitations dictate that our observations
should be validated in larger prospective studies with more
frequent sampling.
In conclusion, our ﬁndings suggest that antiretroviral resistance
alters the relationship between CSF viral loads and better NP
performance. In particular, the presence of antiretroviral resistance
appears to be associated with better NP performance. This may be
mediated by impaired viral ﬁtness and is likely less beneﬁcial than
complete viral suppression by ART. If antiretroviral resistance alters
CSF viral loads, this may in part explain what appears to be a
weakening relationship between CSF viral load andNP performance in
the modern treatment era. Further study of antiretroviral resistance
and HIV neuropathogenesis may contribute to an improved under-
standing of HIV disease in the CNS and perhaps improvements in
treatment options for HAND.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.virol.2009.08.007.
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